Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)
Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)
Status
Status :
Completed
Type of study
Phase III
Min. Age
18
Years old
Max. Age
75
Years old
Gender
Female
Therapeutic area :
Oncology
Disease :
Breast cancer
Study medication :
Vinflunine (Javlor®)
Phase :
Phase III
Start Date :
01 July 2009
End date :
30 January 2014
Study ID :
L00070 IN 308 B0
EudraCT/CTIS number :
2009-011118-47
CT.gov Number :
NCT01091168
Send by email